shutterstock_138095450

Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

pharmafile | February 14, 2019 | News story | Sales and Marketing |  Clinigen, Novartis, Proleukin, pharma 

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant interleukin-2) to Clinigen in a deal worth $210 million, it has emerged.

The agreement breaks down into an initial payment by Clinigen of $120 million, with $60 million to follow deferred over the 12 months following the deal’s completion. The rest will be paid in milestone payments, subject to sales performance.

Under the terms of the deal, Clinigen will gain global rights to its new therapy and become its sole license holder, after it purchased the rights to the drug outside the US in July last year.

Annual revenues of Proleukin have hit approximately $60 million in recent years, according to IQVIA. It is already approved in the US for metastatic melanoma and metastatic renal cell carcinoma.

Advertisement

David Bryant, Chief Business Officer at Clinigen, said of the deal: “Proleukin is an important medicine that has demonstrated complete responses in some patients, with evidence of cancer free survival over 15 years. We believe that its use in emerging treatment regimens will continue to help people fight cancer for years to come.” 

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Scotland starts newborn screening for SMA

As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

The Gateway to Local Adoption Series

Latest content